SensoDetect (SDET) Q4 2024 earnings summary

Executive summary

• Expanded international presence with new commercial agreements in the MENA region and a strategic joint venture in China, expected to generate significant revenue and strengthen global positioning.

• First commercial contract signed in the UAE and deepened collaboration with Al Masarat Almutawira Commercial Broker L.L.C.

• Princess Noura University Hospital in Riyadh signed for SensoDetect's ASD study, advancing clinical research.

• Joint venture in China provides guaranteed income and accelerates commercialization in a market valued at SEK 9 billion.

Financial highlights

• Q4 2024 net sales: 83 KSEK (up from 4 KSEK year-over-year); full year 2024: 95 KSEK (up from 20 KSEK).

• Q4 2024 net result: -2,841 KSEK (improved from -4,233 KSEK year-over-year); full year 2024: -9,781 KSEK (down from -8,302 KSEK).

• Q4 2024 EPS: -0.01 SEK (vs. -0.04 SEK); full year 2024 EPS: -0.03 SEK (vs. -0.08 SEK).

• Q4 2024 cash flow from operations: -1,219 KSEK (vs. 2,633 KSEK); year-end cash: 265 KSEK (vs. 39 KSEK).

• Equity ratio at year-end: 71% (up from 57%).

Outlook and guidance

• Joint venture in China ensures at least 7.8 MSEK in guaranteed revenue over two years, with expected acceleration from H2 2026.

• Commercialization in Saudi Arabia expected to accelerate after April 2025, following ASD study results.

• Positive cash flow and significant revenue growth targeted for 2025, supported by new partnerships and capital from exercised warrants.